

CODE/NAME & ADDRESS: C000138355

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO : 0290WJ005159

PATIENT ID : SALUF010392290

CHIENT BATTENT ID: (BOBE49368)

DPAWN

AGE/SEX :31 Years Female

DRAWN :

RECEIVED : 28/10/2023 15:46:42 REPORTED : 28/10/2023 19:30:39

Test Report Status <u>Preliminary</u> Results Biological Reference Interval Units

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOWR BOUFEMPAILED ING **XRAY-CHEST RESULT PENDING ECG RESULT PENDING MEDICAL HISTORY RESULT PENDING ANTHROPOMETRIC DATA & BMI RESULT PENDING GENERAL EXAMINATION RESULT PENDING** CARDIOVASCULAR SYSTEM RESULT PENDING RESPIRATORY SYSTEM **RESULT PENDING** PER ABDOMEN **RESULT PENDING CENTRAL NERVOUS SYSTEM RESULT PENDING MUSCULOSKELETAL SYSTEM RESULT PENDING BASIC EYE EXAMINATION RESULT PENDING BASIC ENT EXAMINATION RESULT PENDING BASIC DENTAL EXAMINATION RESULT PENDING SUMMARY RESULT PENDING FITNESS STATUS RESULT PENDING**

Page 1 Of 13







View Report





CODE/NAME & ADDRESS: C000138355

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO: 0290WJ005159

PATIENT ID : SALUF010392290

CHIENT PATIENT ID: (BOBE49368)

AGE/SEX : 31 Years F

DRAWN :

RECEIVED : 28/10/2023 15:46:42 REPORTED : 28/10/2023 19:30:39

Test Report Status Preliminary Results Units

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOWRESUFEMPAINED ING

ULTRASOUND ABDOMENRESULT PENDINGTMT OR ECHORESULT PENDING

Page 2 Of 13





View Details

View Report





CODE/NAME & ADDRESS: C000138355

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO: 0290WJ005159

PATIENT ID : SALUF010392290 CHEAT PATIENT ID: (BOBE49368) _____

AGE/SEX :31 Years Female

DRAWN :

RECEIVED : 28/10/2023 15:46:42 REPORTED : 28/10/2023 19:30:39

Test Report Status	Preliminary	Results	Biological Reference Interval	Units

HAEMATOLOGY - CBC			
MEDI WHEEL FULL BODY HEALTH CHECKUP BE	LOW 40FEMALE		
BLOOD COUNTS,EDTA WHOLE BLOOD			
HEMOGLOBIN (HB)	13.4	12.0 - 15.0	g/dL
RED BLOOD CELL (RBC) COUNT	4.98 High	3.8 - 4.8	mil/μL
WHITE BLOOD CELL (WBC) COUNT	8.23	4.0 - 10.0	thou/µL
PLATELET COUNT	351	150 - 410	thou/µL
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV)	37.6	36 - 46	%
MEAN CORPUSCULAR VOLUME (MCV)	75.6 Low	83 - 101	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	26.9 Low	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC)	35.6 High	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW)	12.3	11.6 - 14.0	%
MENTZER INDEX	15.2		
MEAN PLATELET VOLUME (MPV)	7.7	6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT			
NEUTROPHILS	69	40 - 80	%
LYMPHOCYTES	26	20 - 40	%
MONOCYTES	04	2 - 10	%
EOSINOPHILS	01	1 - 6	%
BASOPHILS	00	0 - 2	%
ABSOLUTE NEUTROPHIL COUNT	5.68	2.0 - 7.0	thou/µL
ABSOLUTE LYMPHOCYTE COUNT	2.14	1 - 3	thou/µL
ABSOLUTE MONOCYTE COUNT	0.33	0.20 - 1.00	thou/µL
ABSOLUTE EOSINOPHIL COUNT	0.08	0.02 - 0.50	thou/µL

Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive

Proite

Dr.Arpita Pasari, MD Consultant Pathologist





Page 3 Of 13

liew Details

View Report





CODE/NAME & ADDRESS : C000138355
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO: 0290WJ005159

i PATIENT ID : SALUF010392290

CHIENT BATTENT ID: (BOBE49368)

AGE/SEX :31 Years

Female

DRAWN :

RECEIVED :28/10/2023 15:46:42 REPORTED :28/10/2023 19:30:39

Test Report Status Preliminary Results Biological Reference Interval Units

patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Popita

Dr.Arpita Pasari, MD Consultant Pathologist





Page 4 Of 13

liew Details

) (i ---- D -----





Female

mm at 1 hr

REF. DOCTOR: DR. MEDI WHEEL FULL BODY HEALTH PATIENT NAME: SALUJA NANCY (BOBE49368)

CHECKUP BELOW 40FEMALE AGE/SEX: 31 Years

CODE/NAME & ADDRESS : C000138355 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

ACCESSION NO: 0290WJ005159

PATIENT ID : SALUF010392290

CHIENT BATTENT ID: (BOBE49368)

DRAWN

RECEIVED: 28/10/2023 15:46:42 REPORTED :28/10/2023 19:30:39

Test Report Status Results **Biological Reference Interval Preliminary** Units

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD

E.S.R 15 0 - 20

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE **BLOOD**

Non-diabetic: < 5.7 % HBA1C 5.7

> Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)

116.9 High ESTIMATED AVERAGE GLUCOSE(EAG) < 116.0 mg/dL

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sédimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy,

Estrogen medication, Aging.
Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

salicylates)

REFERENCE :

- 1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:
- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2. Diagnosing diabetes.3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

Dr. Arpita Pasari, MD **Consultant Pathologist** Page 5 Of 13





View Report



8800465156



REF. DOCTOR: DR. MEDI WHEEL FULL BODY HEALTH PATIENT NAME: SALUJA NANCY (BOBE49368) CHECKUP BELOW 40FEMALE

CODE/NAME & ADDRESS : C000138355 ACCESSION NO: 0290WJ005159 AGE/SEX :31 Years ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID DRAWN : SALUF010392290

F-703, LADO SARAI, MEHRAULISOUTH WEST

GETENT BATTENT ID: (BOBE49368) RECEIVED: 28/10/2023 15:46:42 **DELHI** REPORTED :28/10/2023 19:30:39 **NEW DELHI 110030**

Test Report Status Results Biological Reference Interval Units **Preliminary**

1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

2. eAG gives an evaluation of blood glucose levels for the last couple of months. 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

- **HbA1c Estimation can get affected due to :**1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss,hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days. 2. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.
- 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.
- 4. Interference of hemoglobinopathies in HbA1c estimation is seen in
- a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
- b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
- c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Dr. Arpita Pasari, MD **Consultant Pathologist**





Page 6 Of 13

View Report





PATIENT NAME: SALUJA NANCY (BOBE49368) REF. DOCTOR: DR. MEDI WHEEL FULL BODY HEALTH

CHECKUP BELOW 40FEMALE

CODE/NAME & ADDRESS : C000138355 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

ACCESSION NO: 0290WJ005159

CHIENT BATTENT ID: (BOBE49368)

PATIENT ID : SALUF010392290

DRAWN

AGE/SEX :31 Years

RECEIVED: 28/10/2023 15:46:42 REPORTED :28/10/2023 19:30:39

Biological Reference Interval Test Report Status Results Units **Preliminary**

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE O **RH TYPE POSITIVE**

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr. Arpita Pasari, MD **Consultant Pathologist**





Page 7 Of 13





REF. DOCTOR: DR. MEDI WHEEL FULL BODY HEALTH PATIENT NAME: SALUJA NANCY (BOBE49368) CHECKUP BELOW 40FEMALE

CODE/NAME & ADDRESS : C000138355 ACCESSION NO: 0290WJ005159 AGE/SEX :31 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

PATIENT ID : SALUF010392290 CHIENT BATTENT ID: (BOBE49368)

DRAWN

RECEIVED: 28/10/2023 15:46:42 REPORTED :28/10/2023 19:30:39

Biological Reference Interval Units Test Report Status Results **Preliminary**

BIOCHEMISTRY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR)	105 High	74 - 99	mg/dL
---------------------------	----------	---------	-------

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR) 107 Normal: < 140, mg/dL

> Impaired Glucose Tolerance: 140-199 Diabetic > or = 200

LIPID PROFILE WITH CALCULATED LDL

CHOLESTEROL, TOTAL	165	Desirable: <200	mg/dL
--------------------	-----	-----------------	-------

BorderlineHigh: 200-239

High: > or = 240

TRIGLYCERIDES 175 High Desirable: < 150 mg/dL

Borderline High: 150 - 199

High: 200 - 499

Very High: > or = 500HDL CHOLESTEROL

43 mg/dL < 40 Low

> or = 60 High CHOLESTEROL LDL 87 Adult levels:

mg/dL

Optimal < 100

Near optimal/above optimal:

100-129

Borderline high: 130-159

High: 160-189 Very high : = 190

NON HDL CHOLESTEROL 122 Desirable: Less than 130 mg/dL

35.0 High

Above Desirable: 130 - 159 Borderline High: 160 - 189

High: 190 - 219

Very high: > or = 220

CHOL/HDL RATIO 3.8 3.3 - 4.4

0.5 - 3.0 Desirable/Low Risk LDL/HDL RATIO 2.0

3.1 - 6.0 Borderline/Moderate

Risk

< or = 30

>6.0 High Risk

Dr. Arpita Pasari, MD **Consultant Pathologist**



Page 8 Of 13

VERY LOW DENSITY LIPOPROTEIN

Tel: 0731 2490008



mg/dL



CODE/NAME & ADDRESS: C000138355

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO : 0290WJ005159

PATIENT ID : SALUF010392290 CHEAT PATIENT ID: (BOBE49368) AGE/SEX :31 Years

DRAWN :

RECEIVED : 28/10/2023 15:46:42 REPORTED :28/10/2023 19:30:39

	İ	<u> </u>	
Test Report Status <u>Preliminary</u>	Results	Biological Reference I	nterval Units
LIVER FUNCTION PROFILE, SERUM			
BILIRUBIN, TOTAL	0.48	0.0 - 1.2	mg/dL
BILIRUBIN, DIRECT	0.20	0.0 - 0.2	mg/dL
BILIRUBIN, INDIRECT	0.28	0.00 - 1.00	mg/dL
TOTAL PROTEIN	7.9	6.4 - 8.3	g/dL
ALBUMIN	4.9	3.50 - 5.20	g/dL
GLOBULIN	3.0	2.0 - 4.1	g/dL
ALBUMIN/GLOBULIN RATIO	1.6	1.0 - 2.0	RATIO
ASPARTATE AMINOTRANSFERASE(AST/SGOT)	14	UPTO 32	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT)	14	UPTO 34	U/L
ALKALINE PHOSPHATASE	77	35 - 104	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT)	22	5 - 36	U/L
LACTATE DEHYDROGENASE	179	135 - 214	U/L
BLOOD UREA NITROGEN (BUN), SERUM	173	133 211	-, -
BLOOD UREA NITROGEN	6	6 - 20	mg/dL
CREATININE, SERUM		5 _5	J ,
CREATININE	0.54	0.50 - 0.90	mg/dL
BUN/CREAT RATIO			5 ,
BUN/CREAT RATIO	11.11	5.0 - 15.0	
URIC ACID, SERUM			
URIC ACID	3.7	2.6 - 6.0	mg/dL
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN	7.9	6.4 - 8.3	g/dL
ALBUMIN, SERUM			
ALBUMIN	4.9	3.5 - 5.2	g/dL
GLOBULIN			
GLOBULIN	3.0	2.0 - 4.1	g/dL
ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM	141.0	136.0 - 146.0	mmol/L
POTASSIUM, SERUM	4.88	3.50 - 5.10	mmol/L
CHLORIDE, SERUM	103.1	98.0 - 106.0	mmol/L

Popila

Dr.Arpita Pasari, MD Consultant Pathologist





Page 9 Of 13

View Details

View Report





REF. DOCTOR: DR. MEDI WHEEL FULL BODY HEALTH PATIENT NAME: SALUJA NANCY (BOBE49368) CHECKUP BELOW 40FEMALE

CODE/NAME & ADDRESS : C000138355 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

ACCESSION NO: 0290WJ005159

CHIENT BATTENT ID: (BOBE49368)

PATIENT ID : SALUF010392290 AGE/SEX

Female

DRAWN

RECEIVED: 28/10/2023 15:46:42

REPORTED: 28/10/2023 19:30:39

:31 Years

Test Report Status Results Biological Reference Interval Units **Preliminary**

Interpretation(s)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Increased in:Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs:corticosteroids, phenytoin, estrogen, thiazides.

Decreased in : Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic

index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas.It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic

syndrome, Protein-losing enteropathy etc. **Albumin** is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc BLOOD UREA NITROGEN (BUN), SERUM-**Causes of Increased** levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol,

Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

• Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to: Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels: Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome Causes of decreased levels: Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN SCRIMM is a bischoping level for massuring that the protein in action is protein in the calculation of all levels and a large of a level of a large of a larg

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. **Higher-than-normal levels may be due to:** Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr. Arpita Pasari, MD Consultant Pathologist Page 10 Of 13





View Details

View Report





CODE/NAME & ADDRESS : C000138355
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO : **0290WJ005159**

i PATIENT ID : SALUF010392290

CHIENT BATTENT ID: (BOBE49368)

AGE/SEX :31 Years

Female

DRAWN :

RECEIVED : 28/10/2023 15:46:42 REPORTED :28/10/2023 19:30:39

Test Report Status <u>Preliminary</u> Results Biological Reference Interval Units

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW

APPEARANCE CLEAR

CHEMICAL EXAMINATION, URINE

5.0 4.7 - 7.5SPECIFIC GRAVITY >=1.030 1.003 - 1.035 **PROTEIN** NOT DETECTED NOT DETECTED **GLUCOSE** NOT DETECTED NOT DETECTED KETONES NOT DETECTED NOT DETECTED **BLOOD** NOT DETECTED NOT DETECTED **BILIRUBIN** NOT DETECTED NOT DETECTED UROBILINOGEN **NORMAL NORMAL NITRITE NOT DETECTED** NOT DETECTED LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS

NOT DETECTED

NOT DETECTED

/HPF
PUS CELL (WBC'S)

1-2

0-5

/HPF
EPITHELIAL CELLS

1-2

0-5

/HPF

CASTS NOT DETECTED
CRYSTALS NOT DETECTED

BACTERIA NOT DETECTED NOT DETECTED
YEAST NOT DETECTED NOT DETECTED

REMARKS Please note that all the urinary findings are confirmed manually as well.

Dr. Arnita Pasari.

Dr.Arpita Pasari, MD Consultant Pathologist





Page 11 Of 13

View Details

View Report







CODE/NAME & ADDRESS : C000138355

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO : **0290WJ005159**

PAΠENT ID : SALUF010392290

_UF010392290 DRAWN

3rd Trimester: 0.21 - 3.15

CHIENT BATIENT ID: (BOBE49368)

AGE/SEX : 31 Years Femal

DRAWN :

RECEIVED : 28/10/2023 15:46:42 REPORTED :28/10/2023 19:30:39

Test Report Status <u>Preliminary</u> Results Biological Reference Interval Units

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

THYROID PANEL, SERUM

THYROID PANEL, SERUM		
T3	128.80	Non-Pregnant Women ng/dL 80.0 - 200.0 Pregnant Women 1st Trimester:105.0 - 230.0 2nd Trimester:129.0 - 262.0 3rd Trimester:135.0 - 262.0
T4	8.46	Non-Pregnant Women µg/dL 5.10 - 14.10 Pregnant Women 1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70
TSH (ULTRASENSITIVE)	3.010	Non Pregnant Women µIU/mL 0.27 - 4.20 Pregnant Women 1st Trimester: 0.33 - 4.59 2nd Trimester: 0.35 - 4.10

End Of Report
Please visit www.agilusdiagnostics.com for related Test Information for this accession

Apita

Dr.Arpita Pasari, MD Consultant Pathologist





Page 12 Of 13

iew Details

View Report







CODE/NAME & ADDRESS: C000138355

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO: 0290WJ005159

РАПЕНТ ID : SALUF010392290 GBIENT PATIENT ID: (BOBE49368) AGE/SEX :31 Years Female

DRAWN :

RECEIVED : 28/10/2023 15:46:42

REPORTED :28/10/2023 19:30:39

Test Report Status <u>Preliminary</u> Results Biological Reference Interval Units

CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

Agilus Diagnostics Ltd

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Pepita

Dr.Arpita Pasari, MD Consultant Pathologist





Page 13 Of 13

View Details

View Report

